Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001641172-25-014002
Filing Date
2025-06-06
Accepted
2025-06-06 15:13:25
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 5282
  Complete submission text file 0001641172-25-014002.txt   6842
Mailing Address 455 E. MEDICAL CENTER BLVD SUITE 300 SUITE 300 HOUSTON TX 77598
Business Address 455 E. MEDICAL CENTER BLVD SUITE 300 HOUSTON TX 77598 281-671-5150
FibroBiologics, Inc. (Subject) CIK: 0001958777 (see all company filings)

EIN.: 863329066 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-94820 | Film No.: 251030220
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 1414 HORSESHOE DR. SUGAR LAND TX 77478
Business Address
Newlin Michael F. (Filed by) CIK: 0002067695 (see all company filings)

Type: SCHEDULE 13G